Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7986517 | 0.84 | LIMK2 (0.48) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL6152127 | 0.81 | HPGD (0.49) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL25580911 | 0.80 | HPGD (0.48) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL7985858 | 0.79 | KDM4E (0.49) | KDM4EPKMGPR119LIMK2SMN1; SMN2 | |
| SCHEMBL1401260 | 0.79 | HPGD (0.53) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL6402146 | 0.78 | EPHX1 (0.41) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL5135436 | 0.78 | HPGD (0.44) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL5570674 | 0.78 | HPGD (0.51) | KDM4EPKMHPGDRECQLEPHX1 | |
| SCHEMBL15507268 | 0.77 | GPR119 (0.55) | GPR119 | |
| SCHEMBL30271580 | 0.77 | ATM (0.41) | HPGDEPHX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | KDM4E 470/4885PKM 3864/4885HPGD 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.